SCHEDULE 13G: Janus Henderson Group and Affiliates Disclose Significant Passive Stakes in Protara Therapeutics
Beneficial Ownership Disclosure
Janus Henderson Group PLC and its affiliate, Janus Henderson Biotech Innovation Master Fund Ltd, have disclosed passive beneficial ownership stakes of 6.6% and 6.0% respectively, in Protara Therapeutics, Inc. common stock as of December 31, 2024.
Summary
- Janus Henderson Group PLC reported beneficial ownership of 2,271,832 shares of Protara Therapeutics, Inc. common stock, representing 6.6% of the class.
- Janus Henderson Biotech Innovation Master Fund Ltd reported beneficial ownership of 5,448,687 shares of Protara Therapeutics, Inc. common stock, representing 6.0% of the class.
- Both reporting entities, indirect subsidiaries of Janus Henderson, are classified as an Investment Adviser (IA), Parent Holding Company (HC), or Investment Company (IV).
- The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Protara Therapeutics, Inc.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing disclosing passive beneficial ownership and does not contain information that would significantly alter the sentiment towards the issuer.
Positives
- The disclosure of significant stakes by Janus Henderson Group PLC and its affiliate indicates institutional investment in Protara Therapeutics, Inc.
Negatives
- The document does not contain any negative information regarding Protara Therapeutics, Inc.'s financial performance or operational status.
Risks
- This Schedule 13G filing does not contain information regarding specific risks related to Protara Therapeutics, Inc.'s operations or financial health.
Future Outlook
The document is a regulatory filing disclosing beneficial ownership and does not provide any forward-looking statements or guidance regarding Protara Therapeutics, Inc.'s future outlook.
Industry Context
This filing represents a routine disclosure of significant passive institutional ownership, a common occurrence across all publicly traded sectors, including the biotechnology industry, where institutional investment is a key component of market liquidity and valuation.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional holdings, which can influence market perception and liquidity.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires filing of this statement (end of reporting period). |
| 02/14/2025 | Date of filing of this Schedule 13G statement. |
Keywords
SEC filing, Schedule 13G, beneficial ownership, institutional investor, Janus Henderson Group, Protara Therapeutics, common stock, investment adviser, biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.